Pulsing cellular dynamics in genetic circuits have been shown to provide critical capabilities to cells in stress response, signaling and development. Despite the fascinating discoveries made in the past few years, the mechanisms and functional capabilities of most pulsing systems remain unclear, and one of the critical challenges is the lack of a technology that allows pulsatile regulation of transgene expression both in vitro and in vivo. Here, we describe the development of a synthetic BRET-based transgene expression (LuminON) system based on a luminescent transcription factor, termed luminGAVPO, by fusing NanoLuc luciferase to the light-switchable transcription factor GAVPO. luminGAVPO allows pulsatile and quantitative activation of transgene expression via both chemogenetic and optogenetic approaches in mammalian cells and mice. Both the pulse amplitude and duration of transgene expression are highly tunable via adjustment of the amount of furimazine. We further demonstrated LuminON-mediated blood-glucose homeostasis in type 1 diabetic mice. We believe that the BRET-based LuminON system with the pulsatile dynamics of transgene expression provides a highly sensitive tool for precise manipulation in biological systems that has strong potential for application in diverse basic biological studies and gene- and cell-based precision therapies in the future.

1 Optogenetics & Synthetic Biology Interdisciplinary Research Center, State Key Laboratory of Bioreactor Engineering, Shanghai Collaborative Innovation Center for Biomanufacturing Technology, East China University of Science and Technology, 130 Mei Long Road, Shanghai 200237, China. 2 School of Pharmacy, East China University of Science and Technology, 130 Mei Long Road, Shanghai 200237, China. 3 CAS Center for Excellence in Brain Science and Intelligence Technology, Institute of Neuroscience, Chinese Academy of Sciences, Shanghai 200031, China. 4 Synthetic Biology and Biomedical Engineering Laboratory, Biomedical Synthetic Biology Research Center, Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Dongchuan Road 500, Shanghai 200241, China. These authors contributed equally: Ting Li, Xianjun Chen.

✉email: hfye@bio.ecnu.edu.cn; yiyang@ecust.edu.cn
Being able to analyze gene expression patterns is essential for understanding protein function, biological signaling pathways and cellular responses to external and internal stimuli. Conventionally, scientists assume that under constant external conditions, the concentrations and activities of key cellular regulatory molecules generally remain steady over time or fluctuate stochastically around fixed mean values. However, recent studies have shown that many regulatory proteins, including transcription factors (TFs), are regulated in a pulsatile fashion, leading to a variety of phenotypic consequences, ranging from stress response to differentiation. Despite the fascinating discoveries made in the past few years, it remains unclear what functional capabilities such pulsatile dynamic regulation can provide for cells. In addition, the mechanisms of these pulsing systems have been elucidated in a very limited number of cases, revealing both shared features and qualitative differences across systems. Given the importance of the pulsing systems, developing regulatable transgene systems to precisely control the dynamics of key signaling proteins would be useful for understanding the mechanisms and complex biological functions underlying different pulsing systems.

Previously, chemically regulated gene expression systems have been widely used for the temporal control of gene expression in numerous biological studies. However, gene expression from these systems continues for quite a long time once the inducers are presented, as it takes time for these chemical inducers to be degraded or metabolized. Although gene expression could be terminated by physical removal of the inducers by replacement with fresh medium in vitro, it is almost impossible to dynamically regulate transgene expression in animals simply by controlling the presence or absence of chemical inducers. Thus, these systems are not applicable for controlling the dynamics of regulators in most pulsing systems. To overcome these limitations, a series of light-inducible systems have been developed that allow control of transgene expression with unprecedented spatial and temporal precision. These optogenetic systems provide robust and convenient tools to achieve pulsatile dynamic regulation of regulators, allowing direct comparison between functional outcomes and concentration-time relationships of external stimuli. For example, the LightON system developed by our group was used to dynamically control the expression of the transcription factor Ascl1, a Hes1 target that oscillates in neural progenitors, revealing that the dynamics of Ascl1 expression can influence cell fate. Nevertheless, supplying adequate light intensity to activate these optogenetic systems is a major obstacle for their in vivo application, as transmission of external light through deep tissues is extremely inefficient due to light scatter and tissue absorption. Although surgically implanted optical fibers can be used to efficiently deliver external light, undesirable effects (e.g., photobleaching, phototoxicity) may compromise cell viability and experimental outcomes, thereby imposing significant limitations for potential clinical applications.

To bypass the challenges associated with the delivery of external light, neuroscientists have developed luminescent opsinors by directly coupling bioluminescent proteins to conventional light-sensitive opsinors, allowing interrogation of neuronal circuits at different temporal and spatial resolutions by choosing either extrinsic physical or intrinsic biological light for their activation. Unlike traditional chemical inducers, luciferase substrates could be readily consumed to produce bioluminescence to activate opsinors via bioluminescence resonance energy transfer (BRET). When the substrates were consumed, the activated photosensitive modules gradually recovered to the inactive states, leading to inactivation of opsinors. Thus, these luminescent opsinors allowed regulation of neuron activity in a pulsatile fashion. We therefore hypothesized that similar constructs could be used to develop a BRET-based transgene expression system that allows pulsatile regulation of gene expression both in vitro and in vivo.

Here, we describe the development of a luminescent transcription factor termed luminGAVPO that allows pulsatile and quantitative activation of transgene expression in both mammalian cells and animals in a furimazine- or light irradiance-dependent manner. We further demonstrate the usefulness of the luminGAVPO-based transgene expression system for controlling blood glucose homeostasis in type 1 diabetic mice.

**Results**

**Design and construction of the LuminON transgene expression system.** The light-oxygen-voltage (LOV) domain family of proteins is widespread in biology, imparting sensory responses to signal transduction domains. Dark-state LOV proteins contain an oxidized flavin cofactor that maximally absorbs blue light (λ = 440–480 nm). Upon blue light absorption, a covalent adduct is formed between the C4a position of the noncovalently bound flavin cofactor and the thiol moiety of the active-site cysteine (Ω). Many of these small and light-responsive LOV modules have been used for the construction of several optogenetic systems.

NanoLuc (Nluc), an engineered luciferase derived from a deep sea shrimp, is a small (19 kDa) yet stable luciferase that produces 100-150× brighter and more sustained luminescence than the traditional firefly (Fluc) or Renilla (Rluc) luciferase. In particular, Nluc utilizes its substrate to produce blue light (spectral maximum 454 nm), which matches the absorption spectra of LOV proteins. Taking advantage of these attributes, we sought to utilize Nluc to serve as the luminescence donor to activate its linked LOV-based optogenetic modules, thereby modulating their activities.

To this end, we first attempted to use Nluc to activate the LOVTRAP, an optogenetic approach capable of repeatedly and reversibly controlling protein dissociation using the small protein Zdk that binds to the dark state of LOV. We fused Nluc to the N terminus of the mCherry-LOV2 fusion protein (Supplementary Fig. 1a). When we coexpressed the protein with a mitochondria-anchored mVenus-Zdk protein, both mCherry and mVenus fluorescence accumulated at mitochondria under dark conditions (Supplementary Fig. 1b and c). However, the mCherry fluorescence readily diffused to the cytosol within 5 s after the addition of furimazine or exposure to external blue light (Supplementary Fig. 1b–e); when furimazine was consumed or light illumination ceased, mCherry fluorescence accumulated at mitochondria again (Supplementary Fig. 1d and e). Such translocation of mCherry could be triggered repetitively to the same magnitude with little or no loss in efficacy (Supplementary Fig. 1e). In addition to the LOV-based optogenetic modules, Nluc could also be used to control the recruitment of the CRY2-mCherry-Nluc fusion protein to the plasma membrane, where it localized with CIBN-pmEGFP (Supplementary Fig. 1f–i), by activating the interaction between CRY2 and CIB1. These data indicate that Nluc can serve as the luminescence donor for activation of optogenetic modules with matched spectra with Nluc emission.

We previously developed a series of blue light-inducible transgene expression systems based on Vivid (VVD), the smallest LOV domain-containing protein. Unlike traditional TFs dimerize and bind to the promoter region to directly repress gene transcription or activate gene transcription by a fused transcriptional regulatory domain upon blue light exposure. We next aimed to create a luminescent transcription factor by engineering a chimeric protein that consists of Nluc and a light-switchable transcription factor, GAVPO (Fig. 1a, Supplementary Fig. 2). We constructed different configurations of Nluc-GAVPO fusion proteins by inserting Nluc into the N terminus of the Gal4 domain (NG), C terminus of the VVD domain (CV), and middle of the Gal4 domain (MC).
The transfected cells were induced by furimazine for different durations within 12 h, and Gluc activity was measured 24 h after induction. Ratios were calculated.

Effects on cell proliferation and viability were monitored (Supplementary Fig. 7a), but little effects on cell proliferation and viability were observed (Supplementary Fig. 7b).

**Fig. 1 Design and construction of the LuminON transgene expression system.**

- **a** Schematic representation of the LuminON system. In the presence of furimazine or blue light, luminGAVPO homodimerizes, interacts with UAS<sub>G</sub> elements (5xUAS<sub>G</sub>) and initiates transgene expression of the gene of interest (GOI).
- **b** Schematic representation of the reporter plasmid containing 5xUAS<sub>G</sub> upstream of the TATA box and the transactivator plasmids encoding different configurations of Nluc-GAVPO fusion proteins. Furimazine (FZ)- or blue light-induced Gluc expression by different configurations of Nluc-GAVPO transactivators driven by the CMV or SV40 promoter.
- **c** Quantitative control of Gluc expression by modulating furimazine concentration and blue light intensity. The transfected cells were cultured with different furimazine concentrations (0–25 μM) or light irradiances (0–1.63 W/m<sup>2</sup>). Gluc activity was determined 24 h after induction, and induction ratios were calculated.
- **d** Gluc expression kinetics upon induction by furimazine for different durations. The transfected cells were induced by furimazine for different durations within 12 h, and Gluc activity was measured 24 h after the first induction. Data were normalized to Gluc expression in the cells kept in dark conditions without induction by furimazine.
- **e** LuminON system-mediated Gluc expression in different mammalian cell types. Data were normalized to Gluc expression simultaneously induced by furimazine and external blue light. Data in (c, e, and f) represent the mean ± s.d. from three technical replicates. All the statistical comparison was performed by two-tailed t test. n.s. means not significantly different, *P < 0.05, **P < 0.01, ***P < 0.001. Source data are provided in the Source Data file.

We tested their furimazine- or light-dependent impact on the transcriptional activity of a Gaussia luciferase (Gluc) reporter driven by Gal4 binding sites upstream of a TATA box after transient transfection into HEK293 cells (Supplementary Note 1). These results showed that all the Nluc-GAVPO fusions could significantly activate Gluc expression upon incubation with furimazine (FZ) or illumination with external blue light (Fig. 1c), whereas coexpression of Nluc and GAVPO separately yielded only a response to external blue light (Fig. 1c), indicating that furimazine-induced Gluc expression depends on the close proximity of Nluc and VVD in GaVPO to allow BRET to occur. Further studies showed that the interference of luminGAVPO in the cell supernatants was minimal (Supplementary Fig. 3a). We also noticed that Nluc-GAVPO fusions driven by a strong CMV promoter had higher activation levels than those driven by a weak SV40 promoter, but with much higher background expression in the uninduced states (Fig. 1c). It seemed that high Nluc-GAVPO expression resulted in homodimer formation independent of furimazine or light illumination (Supplementary Fig. 4a), thereby activating promoter activities even under dark conditions, which was further validated by transfecting lower amounts of the CMV-driven NG expression plasmid into cells, resulting in lower background expression and higher induction ratios (Supplementary Fig. 4b and c). Since Nluc-GAVPO with NG configuration had moderate activation levels yet exhibited maximal induction ratio by furimazine, we termed it luminGAVPO (luminescent GAVPO), and the transgene expression system based on luminGAVPO was named the LuminON system.

As luminGAVPO could be activated by either furimazine or external blue light, a digital "OR"-like logic gate was predicted for luminGAVPO-activated transgene expression using furimazine and external blue light as the two inputs. We observed increased Gluc expression along with increasing furimazine or blue light irradiance (Fig. 1d, Supplementary Fig. 3b and c). Such dual inputs also support the development of conceptually complex applications. Notably, although higher concentrations of furimazine could produce brighter and more sustained luminescence (Supplementary Fig. 5a and b), Gluc expression slightly decreased when the furimazine concentration was higher than 5 μM (Fig. 1d, Supplementary Fig. 3b). The maximum induction ratio obtained by induction with furimazine alone could reach ~116-fold when the furimazine concentration was 2.5 μM (Supplementary Fig. 3b), and the induced mRNA could be directly visualized using the Pepper fluorescent RNA recently developed by our group (Supplementary Fig. 6). In addition, highly precise control of transgene expression was achieved by combining the furimazine concentration and light irradiance (Fig. 1d). Notably, furimazine exhibited slight inhibition of protein synthesis at high concentrations with more than 5 μM (Supplementary Fig. 7a), but little effects on cell proliferation and viability were observed (Supplementary Fig. 7b).
While the luminescence exhibited a flash-type profile and could only be sustained for 2–3 h for 2.5–5 μM furimazine (Supplementary Fig. 5), we wondered whether induction by furimazine multiple times could increase the luminescence-mediated activation levels, considering that Nluc is resistant to autoinhibition by its catalytic byproducts. To this end, we induced the cells with multiple rounds of furimazine within 12 h (Supplementary Fig. 8), and Gluc expression was measured 24 h after the first induction. The results showed that Gluc expression increased with increasing round of induction by furimazine (Fig. 1e). Furthermore, the LuminON system exhibited excellent transgene expression properties in various mammalian cell lines, indicating its broad application potential (Fig. 1f).

**Pulsatile activation of transgene expression mediated by luminGAVPO.** As shown previously, Nluc catalyzes furimazine to display a relatively short-lived, flash-type light emission profile (Supplementary Fig. 5). When furimazine is consumed, the activated luminGAVPO is gradually inactivated and dissociates from its cognate DNA binding site, leading to inactivation of transcription (Fig. 2a). Thus, furimazine-induced transgene expression by luminGAVPO would display a pulsatile profile. To validate our hypothesis, we measured the time course of Gluc expression upon furimazine induction. Our results showed that gene transcription and expression occurred rapidly, as shown by the sharp increase in Gluc mRNA levels and protein production in the cells within 2 h after furimazine induction (Fig. 2b, Supplementary Fig. 9). Thereafter, we observed a fast decay in the amount of Gluc mRNA and a plateau in the amount of protein without changing the medium (Fig. 2b, Supplementary Fig. 9), which is consistent with the luminescence profile of Nluc-catalyzed furimazine. Thus, furimazine could induce pulsatile activation of transgene expression, with a 1/2 (the time to reach 50% of maximal expression) of 8.3 ± 0.1 h (Fig. 2a and b). This pulsatile activation profile could be more clearly shown by the increased Gluc production during the indicated time periods, which reflected the rate of Gluc synthesis over time, showing that the Gluc synthesis rate reached a maximum at ~4–6 h after furimazine induction and then sharply decreased (Fig. 2c). Notably,
changing the medium to remove the residual furimazine at 4 h after induction did not significantly alter the kinetics of Gluc expression (Fig. 2b and c), probably because the majority of the furimazine had been consumed within 4 h after induction. In contrast, the commonly used chemical-inducible systems maintained high Gluc synthesis rates and showed a rapid increase in Gluc accumulation even 50 h after induction, with a significantly prolonged $\tau_{1/2}$ (>30 h) (Fig. 2d–l). One exception was the ECR system, in which Gluc production dramatically slowed down after removal of Tebufenozide (TBF) but still with a long $\tau_{1/2}$ of 15.8 ± 1.5 h (Fig. 2k and l). Nevertheless, such reversibility can hardly be applied for in vivo studies. Notably, such in vitro comparison does not necessarily translate to the in vivo situation, as the half-life of various chemicals may differ vastly.

Notably, both the pulse amplitude and duration of transgene expression were highly dependent on the dose of furimazine. Lower doses of furimazine exhibited shorter durations (shortened $\tau_{1/2}$) and smaller amplitudes of pulsatile activation, while higher doses of furimazine had longer durations (prolonged $\tau_{1/2}$) and larger amplitudes (Fig. 2m and n). Such tunability will be especially useful for studying pulsing systems with different pulsing dynamics. Further studies showed that pulsatile activation mediated by luminGAVPO could be repetitively and reversibly switched on by alternating furimazine induction at 12-h intervals (Fig. 2o, Supplementary Fig. 10).

**Pulsatile activation of transgene expression in mice.** To determine whether luminGAVPO could be used to activate transgene expression in mice, we transfected luminGAVPO and mCherry reporter plasmids into the livers of mice using a hydrodynamic procedure. Marked mCherry fluorescence was observed in the livers of the mice administered furimazine via tail intravenous (IV), intraperitoneal (IP) or intragastric (IG) injection. The livers of the mice kept in the dark showed minimal mCherry fluorescence (Fig. 3b), whereas the livers of the mice kept in the dark showed minimal mCherry fluorescence (Fig. 3b). Similar results were observed in the tibialis posterior muscles transfected with the same plasmids by electroporation and induced by furimazine via IV administration (Fig. 3c–e).

After confirmation of the functionality of luminGAVPO in mice, we next measured the time course of furimazine-induced transgene expression in mice transfected with luminGAVPO and pU5-Gluc plasmids. Gluc expression rapidly occurred and reached a maximum level within 4 h after furimazine induction (Fig. 3f). Unlike reaching a plateau in cultured cells, the Gluc protein level in the bloodstream sharply decreased after reaching a maximum level (Fig. 3f) because the half-life of Gluc in the bloodstream (20 min) is significantly shorter than that in culture medium (6 days). In addition, a lower dose of furimazine exhibited shorter durations and smaller amplitudes of Gluc expression in the bloodstream, consistent with the results from the cultured cells. Moreover, the pulsatile activation profile mediated by luminGAVPO could be repetitively and reversibly induced by administration of furimazine at 8-h intervals (Fig. 3g). Collectively, these results demonstrate that the LuminON system can be used for pulsatile and reversible activation of transgene expression in vivo.
**Pulsatile expression of insulin to enhance blood glucose homeostasis in T1D mice.** Insulin is a peptide hormone secreted by the β cells of the pancreas during nutrient uptake and maintains glucose homeostasis by inhibiting hepatic glucose output while facilitating cellular glucose uptake. This pulsatile secretion of insulin may match the expression profile mediated by luminGAVPO. As a proof-of-concept demonstration of the potential application of the LuminON system for controllable cell therapy, we constructed HEK_{FUR-Gluc-P2A-mINS} cells stably engineered for luminGAVPO-mediated insulin production. To this end, luminGAVPO and UAS_{G}-TATA-Gluc-P2A-mINS expression cassettes were integrated into HEK293T cells using the Sleeping Beauty transposon system for a detailed procedure, see the Online method. Hundreds of clones were picked and validated by detecting Gluc expression with or without induction by furimazine (Supplementary Fig. 11a). Several clones manifesting >30-fold activation of Gluc expression were further validated by the β cells of the pancreas during nutrient uptake and maintains glucose homeostasis by inhibiting hepatic glucose output while facilitating cellular glucose uptake. This pulsatile secretion of insulin may match the expression profile mediated by luminGAVPO. As a proof-of-concept demonstration of the potential application of the LuminON system for controllable cell therapy, we constructed HEK_{FUR-Gluc-P2A-mINS} cells stably engineered for luminGAVPO-mediated insulin production. To this end, luminGAVPO and UAS_{G}-TATA-Gluc-P2A-mINS expression cassettes were integrated into HEK293T cells using the Sleeping Beauty transposon system (for a detailed procedure, see the Online method). Hundreds of clones were picked and validated by detecting Gluc expression with or without induction by furimazine (Supplementary Fig. 11a). Several clones manifesting >30-fold activation of Gluc expression were further validated (Supplementary Fig. 11b and c). The I18 clone that showed high activation level with low background was chosen for further studies (Supplementary Fig. 11b and c). I18 cells were microencapsulated into coherent, semipermeable and immunoprotective alginate-poly-(L-lysine)-alginate beads that allow free diffusion of substances with low molecular weights (<72 kDa) while shielding their cellular content from physical contact with the host’s immune system (Fig. 4a). T1D mice receiving the microencapsulated cells were treated with 5 mg/kg furimazine, and their blood glucose levels were measured after 3 h. T1D mice implanted with HEK_{FUR-Gluc-P2A-mINS} cells exhibited significant restoration of blood glucose levels (Fig. 4b).

In addition, a higher dose of furimazine resulted in more significant restoration of blood glucose and prolonged the maintenance of glucose homeostasis (Fig. 4c). Furthermore, the implanted T1D mice also showed significantly improved glucose tolerance upon furimazine administration (Fig. 4d). Notably, the

![Image](https://www.nature.com/naturecommunications)
implanted T1D mice showed sustainable restoration of blood glucose for up to 13 days (Fig. 4e), consistent with the results of insulin production upon furimazine induction (Fig. 4f). In contrast, T1D mice implanted with the same microencapsulated cells showed a markedly shortened antidiabetic efficacy upon external blue light illumination (Supplementary Fig. 12), probably due to the low tissue permeability of blue light. Notably, IG administration of furimazine has similar effects of controlling blood glucose homeostasis as IP or IV administration (Fig. 4g), which is a critical favorability criterion because it avoids the pain and anxiety caused by the traditional intramuscular injection of insulin.

Keeping blood glucose levels in the target range during the day is important for T1D patients, especially after food intake. Therefore, T1D patients always need intramuscular injections of insulin before meals to avoid a sharp rise in blood glucose levels (Fig. 4b)\(^6\), which is both inconvenient and painful. Here, we attempted to maintain blood glucose homeostasis by oral administration of furimazine instead of traditional intramuscular injection of insulin before and after meals (Fig. 4b). Briefly, T1D mice with implants were orally administered different dosages of furimazine at 2 h or 3 h before feeding, and blood glucose levels were monitored before and after feeding (Fig. 4i and j). We observed narrow fluctuations in glucose levels before and after feeding compared to the trend in control mice kept only in dark feeding (Fig. 4i and j, Supplementary Fig. 13a and b). Intriguingly, the optimal dosage and time for furimazine administration were closely correlated with the feeding intervals. For example, if the feeding interval was 4 h, administration of 5 mg/kg furimazine 2 h before feeding was optimal; if the feeding interval was 6 h, administration of 7 mg/kg furimazine 3 h before feeding was optimal (Fig. 4i and j). These correlations were mainly contributed by the expression profiles induced by different dosages of furimazine, providing extremely flexible options for potential clinical applications in the future. Further studies showed that oral administration of furimazine twice daily at a dosage of 14 mg/kg for a total of 7 days had little toxicity to the animals, as shown by the little difference in body weight and organ sections between the mice treated with furimazine or not (Supplementary Fig. 14). Notably, a single dose of up to 280 mg/kg furimazine by oral administration also showed little toxicity (Supplementary Fig. 15). Collectively, LuminON system can serve as a valuable and safe tool for precise controllable cell therapy.

**Discussion**

BRET-based technologies have been widely used for real-time detection of protein–protein interactions\(^{47}\) and for construction of biosensors\(^{48-50}\) and bioluminescent–fluorescent proteins\.^{51}\) In 2013, BRET technology was first applied in optogenetics to engineer luminopsins, the fusion proteins of luciferase and opsin\(^{15,16}\). Unlike traditional optogenetic approaches, the use of luminopsins allows interrogation of neuronal circuits at different temporal and spatial resolutions by choosing either extrinsic physical light or intrinsic biological light for their activation\(^{15,16}\). Compared to the luciferases (GLuc or RLuc) used in luminopsins, NLuc has the advantages of high brightness, no requirement of ATP and resistance to autoinhibition by its catalytic byproducts\.^{32,52}\). In particular, the emission spectrum of NLuc perfectly matches the absorption spectra of the light-sensitive LOV proteins. All these favorable properties enable NLuc to be an ideal luminescence donor to activate LOV protein-based optogenetic systems via BRET. Very recently, a transcription factor SPARK2 that incorporates NLuc to control the light-responsive *Avena sativa* LOV domain (AsLOV2) was engineered to detect protein–protein interactions\.^{53}\). Moreover, a NLuc-based bioluminescent–fluorescent protein (GeNLuc) was engineered to active a series of blue-green optogenetic systems\.^{51}\). Intriguingly, NLuc in both the systems was non-fused to the photosensors, demonstrating that BRET may also occur between NLuc and its non-fused partner photosensor when they are in high concentrations. However, NLuc in these systems does not directly activate the transcription factor, which might lead to delay or low efficiency in transcriptional control. In addition, both systems consisted of multiple protein components, increasing the technical complexities and limiting the portability of these systems. Furthermore, whether these systems allow pulsatile regulation of transgene expression remains to be further studied. In this study, we built a BRET-based transgene expression system in a straightforward manner by directly fusing NLuc to a light-switchable transcription factor. Upon induction by furimazine, the luminescence emitted from NLuc directly activated the proximal VVD domain in luminGAVPO, resulting in dimerization of luminGAVPO and binding of luminGAVPO to its cognate promoter, thereby initiating transcription of the target gene. When furimazine is consumed, the luminGAVPO dimer gradually dissociates from the promoter, leading to inactivation of transcription. Therefore, furimazine-induced transgene expression mediated by luminGAVPO is pulsatile. More importantly, the luminGAVPO-based LuminON system consists of only one integrated genetic cassette, conferring it with all the advantages of single-component optogenetic systems, including speed, simplicity, and versatility\(^{54}\).

The pulsatile expression profile mediated by the LuminON system would be especially useful for the in vivo study of pulse behavior in naturally occurring systems to understand the principles and kinetics underlying such spatiotemporal patterns in gene expression. For example, insulin secretion is normally maintained at low levels in normal conditions but quickly rises after food intake. In type 1 diabetic patients, blood glucose homeostasis is disrupted since the body does not produce enough insulin\(^{40}\). Patients usually administer insulin through various external sources, such as insulin jet injectors and insulin syringes\(^{55}\). The proof-of-concept studies described here show the use of the LuminON system to control the pulsatile and repetitive expression of insulin to enhance blood-glucose homeostasis in T1D mice, which could prevent the hypoglycemia caused by excessive insulin from continuous production by traditional chemical-inducible systems. In particular, since both the pulse amplitude and duration of transgene expression are highly tunable via adjustment of the amounts of furimazine, this system is applicable for T1D patients with different dietary habits, e.g., 3 or 4 meals a day. Additionally, due to the design principle of luminGAVPO, we can further fine-tune the pulse amplitude and duration by modulating the photoadduct decay of the VVD domain\(^{20}\). In principle, VVD mutants with faster photoadduct decay may enable a narrower amplitude and shorter pulse duration of the system, as these mutants can accelerate recovery of the activated luminGAVPO to the inactivated state, resulting in earlier termination of transcription. Therefore, it is possible to realize more precise control of the pulse amplitude and duration for the study of various pulsatile dynamics of different pulsing systems simply by combining different furimazine amounts with different luminGAVPO mutants.

The NLuc bioluminescence system derives from deep sea shrimp and thus is heterogeneous and orthogonal in mammals, indicating the relatively low possibility of cross-talk between the host chassis and the transcription factor or inducer. Furthermore, previous studies have shown that furimazine can cross the blood-brain barrier\(^{34}\), indicating the potential for application of the LuminON system in pulsatile regulation of transgene expression in the brain. All these favorable properties would be useful for expanding the applications of the LuminON system in the future.
In our study, the engineered cells were microencapsulated and implanted intraperitoneally, which allowed free diffusion of substances with low molecular weights (<72 kDa) while shielding their cellular content from physical contact with the host's immune system. However, implantation of the microencapsulated cells may also elicit innate immune-mediated foreign body responses that result in fibrotic deposition, nutrient isolation, and donor tissue necrosis. In order to improve the safety and durability of LumiON system-based gene therapy, the virus vector, e.g., aden-associated virus that has been approved for gene therapy by FDA, can provide an alternative approach to deliver our LumiON system into animals for long-term gene therapy.

Overall, the BRET-based optogenetic device developed in this study can be used to precisely control the dynamics of key signaling proteins in a pulsatile fashion both in vitro and in vivo and can serve as a model system for improved understanding of the principles and kinetics underlying similar pulsing behaviors found in nature, for engineering precise controllable cellular systems in the synthetic biology field, and for providing methodologies for pharmacological interventions.

Methodology

Cell culture and transfection. HEK293, HEK293T, HeLa, COS-7 and U-87 cells (Cell Bank of Chinese Academy of Science) were maintained in Dulbecco’s modified Eagle’s medium (high glucose) (HyClone) supplemented with 10% FBS (Biological Industries) and 1% penicillin-streptomycin 100× solution (HyClone). PC-3, A549 and H1299 cells were grown in RPMI 1640 (HyClone) supplemented with 10% FBS and 1% penicillin-streptomycin 100× solution. All cells were cultured at 37 °C in a humidified atmosphere of 95% air and 5% CO2. Cells were plated in antibiotic-free DMEM (high glucose) or RPMI 1640 supplemented with 10% FBS 16-24 h before transfection.

We typically used Hieff Trans™ liposomal transfection reagent (YEASEN, 40802ES02) for transfection according to the manufacturer’s protocol. In detail, cells were seeded at 70–90% confluence before transfection. For 96-well plates, 0.1 μg of DNA (0.05 μg of transactivator plasmid and 0.05 μg of reporter plasmid) and 0.25 μl of Hieff Trans™ liposomal transfection reagent were diluted in 25 μl of Opti-MEM (GIBCO) and then mixed. The DNA-lipid complex was added to the cells after a 20-min incubation at room temperature.

Light irradiation and furimazine induction. Unless indicated, the transfected cells were kept in the dark for 24 h and then, the medium was replaced with fresh complete serum/antibiotic-containing medium (no phenol red). Then, the transfected cells were illuminated by 1.4 W·m−2 (average irradiance) blue light from an LED lamp (460-nm peak) from below or remained in the dark with or without furimazine before characterization. The LED lamps were controlled with a timer to adjust the overall dose of blue light illumination during the specified period.

The mCherry fluorescence in mouse livers, the livers were dissected from the sacrificed mice 18 h after intravenous injection of plasmids. Images were acquired using an In-Vivo Multispectral System FX (Carestream) with an excitation wavelength of 600/20 nm and an emission wavelength of 670/50 nm. The mCherry fluorescence was resolved from background fluorescence by the Carestream Multispectral processing software.

Cell viability assay. HEK293 cells (1 × 106) were seeded into each well of a 96-well plate and transfected with CMV-NLuc or empty plasmid. Twenty-four hours after transfection, the cells were exposed to different concentrations of furimazine for 48 h, and cell viability was evaluated using Cell Counting Kit-8 (Dojindo Laboratories, Gaithersburg, MD) according to the manufacturer’s protocol. After treatment with CCK8 at 37 °C for 2 h, the absorbance at 450 nm was measured using the Synergy 2 or the Neo2 multi-mode microplate reader (BioTek).

Western blot. For the Western blot analyses, cells were lysed in 1× SDS sample buffer supplemented with a protease/phosphatase inhibitor cocktail (Cell Signaling Technology). Equal amounts of total protein (30–60 μg) were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and electro-transferred onto PVDF membranes. Membranes were incubated with primary antibodies against FLAG (1:1000, Anti-OctA-Probe, Santa Cruz Biotechnology) and β-actin (1:1000, Anti-β-Actin, Santa Cruz Biotechnology), and then with secondary antibodies (1:3000, Anti-rabbit IgG, HRP-linked Antibody, Cell Signaling Technology) conjugated to horseradish peroxidase, followed by addition of chemiluminescence detection mixture (YEASEN, 36208E860) and imaging. The original WB figure of lumixGAVPO was shown in Supplementary Note 2.

Imaging. Unless indicated, confocal imaging for live-cell fluorescence was performed using a Leica TCS SP8 DIVE microscope equipped with an HC PL APO 80×/1.40 OIL objective and an HyD detector. BFP fluorescence was imaged using a 405-nm laser and an emission wavelength range of 415–475 nm. mCherry fluorescence was imaged using a 561-nm laser and an emission wavelength range of 570–650 nm. For imaging of mCherry fluorescence in mouse livers, the livers were dissected from the sacrificed mice 18 h after intravenous injection of plasmids. Images were acquired using an In-Vivo Multispectral System FX (Carestream) with an excitation wavelength of 600/20 nm and an emission wavelength of 670/50 nm. The mCherry fluorescence was resolved from background fluorescence by the Carestream Multispectral processing software.

In the study, the engineered cells were microencapsulated and implanted intraperitoneally, which allowed free diffusion of substances with low molecular weights (<72 kDa) while shielding their cellular content from physical contact with the host's immune system. However, implantation of the microencapsulated cells may also elicit innate immune-mediated foreign body responses that result in fibrotic deposition, nutrient isolation, and donor tissue necrosis. In order to improve the safety and durability of LumiON system-based gene therapy, the virus vector, e.g., aden-associated virus that has been approved for gene therapy by FDA, can provide an alternative approach to deliver our LumiON system into animals for long-term gene therapy.

Overall, the BRET-based optogenetic device developed in this study can be used to precisely control the dynamics of key signaling proteins in a pulsatile fashion both in vitro and in vivo and can serve as a model system for improved understanding of the principles and kinetics underlying similar pulsing behaviors found in nature, for engineering precise controllable cellular systems in the synthetic biology field, and for providing methodologies for pharmacological interventions.
To induce gene expression in mouse muscles, KM mice were electroporated with 50 µg of plasmids with the LumioN system. Electrode needles were inserted into the muscle to a depth of 5 mm together with the syringe. A total of 50 µg of plasmids for the supernatants were measured using a Gaussia luciferase assay kit as described above.

To induce gene expression in mouse muscles, KM mice were electroporated with 50 µg of plasmids with the LumioN system. Electrode needles were inserted into the muscle to a depth of 5 mm together with the syringe. A total of 50 µg of plasmids for the supernatants were measured using a Gaussia luciferase assay kit as described above.

Received: 15 June 2020; Accepted: 21 December 2020; Published online: 27 January 2021

References

1. Levine, J. H., Lin, Y. & Elowitz, M. B. Functional roles of pulsing in genetic circuits. Science 342, 1193–1200 (2013).

2. Benzinger, D. & Khanna, M. Pulsatile inputs achieve tunable attenuation of gene expression variability and graded multi-gene regulation. Nat. Commun. 9, 3521 (2018).

3. Basu, S., Mehrjou, R., Thiberge, S., Chen, M. T. & Weiss, R. Spatiotemporal control of gene expression with pulse-generating networks. Proc. Natl Acad. Sci. USA 101, 6355–6360 (2004).

4. Sael, G. M., Kulkarni, R. P., Dworkin, J., Garcia-Ojalvo, J. & Elowitz, M. B. Tunability and noise dependence in differentiation dynamics. Science 315, 1716–1719 (2007).

5. Meseguer, E., Looer, A., Mock, C. & Lahav, G. Stimulus-dependent dynamics of p35 in single cells. Mol. Syst. Biol. 7, 488 (2011).

6. Albeck, J. G., Mills, B. G. & Bruggje, S. J. Frequency-modulated pulses of ERK activity transmit quantitative proliferation signals. Mol. Cell 49, 249–261 (2013).

7. Lee, R. E., Walker, S. R., Savery, K., Frank, D. A. & Gaudet, S. Fold change of nuclear NF-kappaB determines TNF-induced transcription in single cells. Mol. cell 53, 867–879 (2014).

8. Hjelm, B. E. et al. Mifepristone-inducible transgene expression in neural progenitor cells in vitro and in vivo. Gene Ther. 23, 424–437 (2016).

9. Eisinger, H., Chang, V., Mitch, J. K. & Chen, J. K. Small-molecule regulation of zebrafish gene expression. Nat. Chem. Biol. 3, 154–155 (2007).

10. Panguluri, S. K., Kumar, P. & Palli, S. R. Functional characterization of ecdysone receptor gene switches in mammalian cells. FEBS J. 273, 5550–5563 (2006).

11. Saez, E., No, D., West, A. & Evans, R. M. Inducible gene expression in mammalian cells and transgenic mice. Curr. Opin. Biotechnol. 8, 608–616 (1997).

12. Monsouri, M., Strittmatter, T. & Fussenegger, M. Light-controlled mammalian cells and their therapeutic applications in synthetic biology. Adv. Sci. 6, 1800952 (2019).

13. Yamada, M., Nagasaki, S. C., Ozawa, T. & Imayoshi, I. Light-mediated control of gene expression in mammalian cells. Neuron. Sci. Res. 152, 6–7 (2020).

14. Imayoshi, I. et al. Oscillatory control of factors determining multipotency and fate in mouse neural progenitors. Science 342, 1203–1208 (2013).

15. Berglund, K., Birker, E., Augustine, G. J. & Hochgeschwender, U. Light-emitting channelrhodopsin variants for combined optogenetic and chemical-genetic control of neurons. PloS one 8, e59759 (2013).

16. Berglund, K. et al. Luminoisins integrate opto- and chemogenetics by using physical and biological light sources for opsin activation. Proc. Natl Acad. Sci. USA 113, E358–E367 (2016).

17. Pudasaini, A., El-Arab, K. K. & Zolotowski, B. D. LOV-based optogenetic devices: light-driven modules to impart photoregulated control of cellular signaling. Front. Mol. Biosci. 2, 18 (2015).

18. Salomon, M., Christie, J. M., Knieb, E., Lempert, U. & Briggs, W. R. Photochemical and mutational analysis of the FMN-binding domains of the plant blue light receptor, phototropin. Biochemistry 39, 9401–9410 (2000).

19. Swartz, T. E. et al. The photocycle of a flavin-binding domain of the blue light photoreceptor phototropin. J. Biol. Chem. 276, 36493–36500 (2001).

20. Zolotowski, B. D., Vaccaro, B. & Crane, B. R. Mechanism-based tuning of a LOV domain photoreceptor. Nat. Chem. Biol. 5, 827–834 (2009).

21. El-Arab, K. K., Pudapanni, A. & Zolotowski, B. D. Short LOV proteins in methylocystis reveal insight into LOV domain photocycle mechanisms. PloS one 10, e124874 (2015).

22. Conrad, K. S., Bilwes, A. M. & Crane, B. R. Light-induced subunit dissociation by a light-oxygen-voltage domain photoreceptor from Rhodobacter sphaeroides. Biochemistry 52, 378–391 (2013).

23. Nash, A. I. et al. Structural basis of photosensitivity in a bacterial light-oxygen-voltage/helix-turn-helix (LOV-HTH) DNA-binding protein. Proc. Natl Acad. Sci. USA 108, 9449–9454 (2011).

24. Kennedy, M. J. et al. Rapid blue-light-mediated induction of protein interactions in living cells. Nat. meth. 7, 973–975 (2010).

25. Yazawa, M., Sadagahini, A. M., Hasse, B. & Dolmetsch, R. E. Induction of protein-protein interactions in live cells using light. Nat. Biotechnol. 27, 941–945 (2009).

26. Strickland, D. et al. TULIPs: tunable, light-controlled interacting protein tags for cell biology. Nat. meth. 9, 379–384 (2012).
27. Wang, X., Chen, X. & Yang, Y. Spatiotemporal control of gene expression by a light-switchable transgene system. Nat. methods 9, 266–269 (2012).
28. Remick, C., Schuster, D., Usherenko, S., Essen, L. O. & Taxis, C. A LOV2 domain-based optogenetic tool to control protein degradation and cellular function. Chem. Biol. 20, 619–626 (2013).
29. Motta-Mena, L. B. et al. An optogenetic gene expression system with rapid activation and deactivation kinetics. Nat. Chem. Biol. 10, 196–202 (2014).
30. Chen, X. et al. An extraordinary stringent and sensitive light-switchable gene expression system for bacterial cells. Cell Res. 26, 854–857 (2016).
31. Jayaraman, P. et al. Blue light-mediated transcriptional activation and repression of gene expression in bacteria. Nucleic Acids Res. 44, 6994–7005 (2016).
32. Hall, M. P. et al. Engineered luciferase reporter from a deep sea shrimp utilizing a novel imidazopyrazinone substrate. ACS Chem. Biol. 7, 1848–1857 (2012).
33. Wang, H. et al. LOVTRAP: an optogenetic system for photoinduced protein dissociation. Nat. methods 13, 755–758 (2016).
34. Chen, X. et al. Synthetic dual-input mammalian genetic circuits enable tunable and stringent transcription control by chemical and light. Nucleic Acids Res. 44, 2677–2690 (2016).
35. Xu, X. et al. A single-component optogenetic system allows stringent switch of gene expression in yeast cells. ACS Synth. Biol. 7, 2045–2053 (2018).
36. Chen, X. et al. Visualizing RNA dynamics in live cells with bright and stable fluorescent RNAs. Nat. Biotechnol. 37, 1287–1293 (2019).
37. Li, X. et al. A single-component light sensor system allows highly tunable and direct activation of gene expression in bacterial cells. Nucleic Acids Res. 48, e33 (2020).
38. Liu, F., Song, Y. & Liu, D. Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA. Gene Ther. 6, 1258–1266 (1999).
39. Tannous, B. A. Gaussia luciferase reporter assay for monitoring biological processes in culture and in vivo. Nat. Protoc. 4, 582–591 (2009).
40. Fu, Z., Gilbert, E. R. & Liu, D. Regulation of insulin synthesis and secretion and pancreatic Beta-cell dysfunction in diabetes. Curr. Diabetes Rev. 9, 25–53 (2013).
41. Mates, L. et al. Molecular evolution of a novel hyperactive sleeping beauty transposase enables robust stable gene transfer in vertebrates. Nat. Genet. 41, 753–761 (2009).
42. Jacobs-Tulleeners-Thewis, D. et al. Sustained function of alginate-encapsulated human islet cell implants in the peritoneal cavity of mice leading to a pilot study in a type 1 diabetic patient. Diabetologia 56, 1605–1614 (2013).
43. Vegas, A. J. et al. Combinatorial hydrogel library enables identification of materials that mitigate the foreign body response in primates. Nat. Biotechnol. 34, 153–155 (2016).
44. Vegas, A. J. et al. Long-term glycemic control using polymer-encapsulated human stem cell-derived beta cells in immune-competent mice. Nat. Med. 22, 306–311 (2016).
45. Yang, H. K. & Yoon, K. H. Current status of encapsulated islet transplantation. J. diabetes its complications 29, 737–743 (2015).
46. Advani, A. Positioning time in range in diabetes management. Diabetologia 63, 242–252 (2020).
47. Hamdan, F. F., Percherancier, Y., Breton, B. & Bouvier, M. Monitoring protein-protein interactions in living cells by bioluminescence resonance energy transfer (BRET). Curr. Protocols Neurosci. Chapter 5, Unit 5 23 (2006).
48. Valkovic, A. L. et al. Real-time examination of CAMP activity at relaxin family peptide receptors using a BRET-based biosensor. Pharmacol. Res. Perspect. 6, e00432 (2018).
49. Parag-Sharma, K. et al. Engineered BRET-based biologic light sources enable spatiotemporal control over diverse optogenetic systems. ACS Synth. Biol. 9, 1–9 (2020).
50. Tung, J. K., Gutekunst, C. A. & Gross, R. E. Inhibitory luminescins: genetically-encoded bioluminescent opsins for versatile, scalable, and hardware-independent optogenetic inhibition. Sci. Rep. 5, 14366 (2015).
51. Kim, C. K., Cho, K. F., Kim, M. W. & Ting, A. Y. Luciferase-LOV BRET enables versatile and specific transcriptional readout of cellular protein-protein interactions. elife 8, e45826 (2019).
52. Deisseroth, K. Optogenetics: 10 years of microbial opsins in neuroscience. Nat. Neurosci. 18, 1213–1225 (2015).
53. Castle, J. R., DeVries, J. H. & Kovatchev, B. Future of automated insulin delivery systems. Diabetes Technol. Therapeutica 19, S67–S72 (2017).
54. Germain-Genevois, C., Garandeau, O. & Couillaud, F. Detection of brain tumors and systemic metastases using nanoLuc and fuc for dual reporter imaging. Mol. Imaging Biol. 18, 62–69 (2016).
55. Tuch, B. E. et al. Safety and viability of microencapsulated human islets transplanted into diabetic humans. Diabetes Care 32, 1887–1889 (2009).
56. de Groot, M., Schuurs, T. A. & van Schilfgaarde, R. Causes of limited survival of microencapsulated pancreatic islet grafts. J. Surgical Res. 121, 141–150 (2004).
57. Wang, D., Tai, P. W. L. & Gao, G. Adeno-associated virus vector as a platform for gene therapy delivery. Nat. Rev. Drug Discov. 18, 358–378 (2019).
58. Shao, J. et al. Smartphone-controlled optogenetically engineered cells enable semiautomatic glucose homeostasis in diabetic mice. Sci. Transl. Med. 9, eaal2298 (2017).
59. Ye, H. et al. Pharmaceutically controlled designer circuit for the treatment of the metabolic syndrome. Proc. Natl Acad. Sci. USA 110, 141–146 (2013).
60. Yin, J. et al. A green tea-triggered genetic control system for treating diabetes in mice and monkeys. Sci. Transl. Med. 11, eaav8826 (2019).

Acknowledgements
We thank Dr. Huan Xu at East China University of Science and Technology, Jianhui Yin, Shuai Xue, Guiling Yu, Yang Zhou at East China Normal University for technical assistance. This research was supported by the National Key Research and Development Program of China (2019YFA0904800 and 2017YFA050400 to Y.Y., NSFC (91857202 and 21937004 to Y.Y., 31971349 and 31600688 to X.C. and 31901033 to T.L.), the Shanghai Science and Technology Commission (18JC1411900 to Y.Y., 19ZR1472800 to X.C. and 18JC1411000 to H.Y.), the Shanghai Rising-Star Program to X.C., the Young Elite Scientists Sponsorship Program by CSTC to X.C., the Shanghai Sailing Program (19F1413160 to T.L.), the Fundamental Research Funds for the Central Universities to Y.Y. and X.C., the China Postdoctoral Science Foundation (2019M651413 to T.L.).

Author contributions
Concepts were conceived by Y.Y., H.Y. & X.C.; Y.Y., H.Y., X.C. & T.L. designed the experiments and analyzed the data; T.L. performed live cells experiments. T.L., X.L. and Y.Q. performed plasmid construction. T.L., J.S. and S.L. performed mice experimental. L. Z. and Y.Z. gave technical support and conceptual advice. Y.Y., H.Y., X.C. and T.L. wrote the manuscript.

Competing interests
Y.Y., X.C., and T.L. are named inventors of patent application no. 2020115018802. The remaining authors declare no competing interests.

Additional information
Supplementary information is available for this paper at https://doi.org/10.1038/s41467-021-20913-1.

Correspondence and requests for materials should be addressed to H.Y. or Y.Y.

Peer review information Nature Communications thanks Paolo Fiorina, Ute Hochgeschwender and the other, anonymous, reviewer(s) for their contribution to the peer review of this work. Peer reviewer reports are available.

Reprints and permission information is available at http://www.nature.com/reprints

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

© The Author(s) 2021